Clinical trial
89Zr-bevacizumab PET Imaging as Predictive Biomarker for Everolimus Efficacy in Patients With Neuroendocrine Tumors
NCT01338090 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- 89Zr-bevacizumab PET Imaging as Predictive Biomarker for Everolimus Efficacy in Patients With Neuroendocrine Tumors
- Lead sponsor
- University Medical Center Groningen
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 30, 2010
- Completion date
- March 31, 2012
- Enrollment
- 14 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.